Zydus Worldwide Commences Tender Offer to Acquire Assertio Holdings for $23.50/Share
Summary
Zydus Worldwide DMCC has formally commenced its cash tender offer to acquire all outstanding shares of Assertio Holdings, Inc. for $23.50 per share, following the definitive merger agreement announced on May 13, 2026.
Key Events
-
Tender Offer Commenced
Zydus Worldwide DMCC's subsidiary, Zara Merger Sub Inc., has commenced the cash tender offer to acquire Assertio Holdings, Inc. on May 18, 2026.
-
Acquisition Price Confirmed
All outstanding shares of Assertio common stock are being sought for $23.50 per share in cash, consistent with the definitive merger agreement announced on May 13.
-
Convertible Notes Impact
The merger constitutes a 'Fundamental Change,' granting Convertible Note holders rights to repurchase at principal plus interest or convert at an increased rate.
-
Follows Bidding War
This tender offer finalizes the acquisition process after Assertio terminated a previous merger agreement with Garda Therapeutics for a lower price, providing a definitive outcome for shareholders.
Analysis
This filing marks the official commencement of the tender offer by Zydus Worldwide DMCC to acquire Assertio Holdings. While the definitive merger agreement for $23.50 per share was announced on May 13, the launch of the tender offer is the critical step that allows shareholders to tender their shares and realize the acquisition price. This follows a recent bidding war, with Zydus's offer surpassing a previous agreement with Garda Therapeutics. The offer price of $23.50 is near the company's 52-week high, providing a clear exit for shareholders.
At the time of this filing, ASRT was trading at $23.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $150.7M. The 52-week trading range was $8.61 to $23.36. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.